A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma

NCT06656221 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Mantle Cell Lymphoma

Interventions

DRUG: Obinutuzumab
DRUG: Glofitamab
DRUG: Bortezomib
DRUG: Orelabrutinib

Sponsor

Ruijin Hospital